Postavení venlafaxinu v léčbě depresivních a úzkostných poruch
| Title in English | The place of venlafaxine in the treatment of depressive and anxiety disorders |
|---|---|
| Authors | |
| Year of publication | 2008 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| MU Faculty or unit | |
| Citation | |
| Field | Psychiatry, sexuology |
| Keywords | dual action antidepressants; depressive disorder; anxiety disorder; response; remission; venlafaxine; desvenlafaxine |
| Description | Dual-action antidepressants SNRIs have recently come into the limelight. Venlafaxine, the longest available SNRI, has also been the subject of a number of review articles in the Czech literature. This article summarizes the most recent comparisons of venlafaxine with other antidepressants, thus defining the place of the drug a mong other antidepressants. Antidepressants that influence the availability of more than one of the major neurotransmitters appear to have a more pronounced effect. In the Czech Republic, venlafaxine is currently available in the better tolerated extended-release form. Desvenlafaxine, an active metabolite of venlafaxine, has shown great promise in clinical practice. One of the greatest advantages of desvenlafaxine is that it is not metabolized via CYP2D6 and, unlike venlafaxine, does not inhibit CYP2D6. This fact would have the practical benefit of reducing the risk of drug interactions. |
| Related projects: |